Alle Studien
Aktiv, aber nicht rekrutierendPHASE2INTERVENTIONELL

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

The AGLOW study is a research project focusing on a new medicine, VX-407, for adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD). This condition causes fluid-filled sacs (cysts) to grow in the kidneys, which can lead to kidney damage over time. The main goal of this study is to find out if VX-407 can slow down the growth of these cysts by measuring changes in kidney size. Researchers will also be checking if the medicine is safe to use, if people can tolerate it well, and how the body processes it. This early-stage study is an important step in understanding if VX-407 could be a future treatment option for ADPKD, specifically for patients with certain genetic features.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE2
Sponsor
Vertex Pharmaceuticals Incorporated
Einschreibeziel
26
Starten
19. Nov. 2025
Geschätzte Fertigstellung
31 Dez 2027

Worum geht es in dieser Studie?

This study, named AGLOW, is investigating a new medication called VX-407 for people living with Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a genetic condition where fluid-filled sacs, known as cysts, develop and multiply in the kidneys. Over time, these cysts can enlarge the kidneys and reduce their ability to function properly, potentially leading to kidney failure.

The main aim of this research is to see how VX-407 affects the size of the kidneys, as increased kidney size is often a sign of ADPKD progressing. Researchers will be measuring your kidney volume (adjusted for your height) to see if the medicine can slow down cyst growth. They also want to understand if VX-407 is safe for patients to use, if it causes any side effects, and how the body absorbs, distributes, and removes the medicine (what scientists call 'pharmacokinetics').

This is an early-stage study (Phase 2a), which means it's one of the first times this specific medicine is being tested in a larger group of patients to assess its effectiveness and safety. The insights gained from AGLOW will be crucial in deciding if VX-407 has the potential to become a treatment for ADPKD, particularly for individuals who have specific genetic changes in their PKD1 gene.

Wichtige Erkenntnisse

  • This study is testing a new medicine (VX-407) for ADPKD.
  • It aims to see if the medicine can slow down kidney cyst growth.
  • Participation requires regular hospital visits and health monitoring.
  • You must be 18-65 years old and have a specific type of ADPKD.
  • Potential benefits and risks will be fully explained before you decide to join.
  • Sie können jederzeit von der Studie zurücktreten.

Wer könnte berechtigt sein?

To join this study, you must have been diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and be willing to attend all scheduled appointments and follow the study instructions. Your kidney cysts would also need to meet certain measurements seen on a special MRI scan (Mayo imaging classification 1B with a kidney size of at least 250 mL/m, 1C, 1D, or 1E).

Your kidneys also need to be working at a certain level. Specifically, your estimated kidney function (eGFR) must be 25 millilitres per minute per 1.73 square metre or higher. You must be between 18 and 65 years old, and the study is open to both men and women.

There are also some reasons why you wouldn't be able to join. For example, if you have another kidney condition not related to ADPKD, or if you've had a kidney or other organ transplant, or if you've had a kidney removed. People who are currently on dialysis or expect to start dialysis within the next year would also not be able to participate. The study team will review all your medical information to make sure it's safe and appropriate for you to join.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Do you have a diagnosis of ADPKD?
  2. Sind Sie zwischen 18 und 65 Jahre alt?
  3. Are you able to attend clinic visits regularly?
  4. Has an MRI scan shown your kidney condition meets certain criteria (like Mayo 1B with a specific size, 1C, 1D, or 1E)?
  5. Is your kidney function (eGFR) at least 25 mL/min/1.73 m² or higher?
  6. Have you not had a kidney transplant or other major organ transplant?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in the AGLOW study, you will have regular visits to the clinic so the research team can monitor your health and the effects of the study medicine. These visits will involve various tests and assessments, including blood and urine samples, and possibly repeat MRI scans to measure your kidney size. You will be taking the study medicine, VX-407, as directed by the study team. You will also have follow-up appointments after you stop taking the medicine to ensure your health is still being monitored. The total duration of your involvement in the study will be explained in detail by the research team.

Potenzielle Risiken und Vorteile

Taking part in any clinical study carries potential benefits and risks. For this study, a potential benefit could be that VX-407 might help slow down the progression of your ADPKD, although this is not guaranteed as it's a new medicine being tested. It's also possible you may not experience any direct benefits. Potential risks could include side effects from the medication or discomfort from study procedures like blood tests or MRI scans. The research team will explain all known or expected risks in detail. Remember, participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Standorte (43)

  • Alabama Kidney Research
    Verifizierte Postleitzahl
    Alabaster, Vereinigte Staaten
  • UAB Nephrology Research at CH19
    Verifizierte Postleitzahl
    Birmingham, Vereinigte Staaten
  • Kaiser Permanente Los Angeles Medizinisches Zentrum
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • UCSF Clinical Research Center at Parnassus
    Verifizierte Postleitzahl
    San Francisco, Vereinigte Staaten
  • Nephrology & Hypertension Associates, PC
    Verifizierte Postleitzahl
    Middlebury, United States
  • Yale University - Yale Nephrology Clinical Research Clinic
    Verifizierte Postleitzahl
    New Haven, Vereinigte Staaten
  • Mayo Clinic - Jacksonville
    Verifizierte Postleitzahl
    Jacksonville, Vereinigte Staaten
  • Emory School of Medicine - Renal Division
    Verifizierte Postleitzahl
    Atlanta, Vereinigte Staaten
  • Renal Associates
    Verifizierte Postleitzahl
    Columbus, Vereinigte Staaten
  • UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology
    Verifizierte Postleitzahl
    Chicago, Vereinigte Staaten
  • University of Iowa Health Care Medical Center- Nephrology
    Verifizierte Postleitzahl
    Iowa City, Vereinigte Staaten
  • Clinical & Translational Science Unit (CTSU) - Nephrology
    Verifizierte Postleitzahl
    Kansas City, Vereinigte Staaten

Häufige Fragen

What is ADPKD?

ADPKD stands for Autosomal Dominant Polycystic Kidney Disease. It's a genetic condition where fluid-filled sacs called cysts grow in your kidneys, which can affect their function over time.

What is VX-407?

VX-407 is a new medicine being studied. This research project is trying to find out if it's safe and effective for treating ADPKD.

Werde ich das neue Medikament auf jeden Fall bekommen?

In some studies, participants are randomly assigned to receive the study medicine or a placebo (a dummy medicine). The researchers will explain exactly what this means for you.

Will I have to pay to join this study?

No, you will not have to pay to participate in the study, and study-related medical care and the study medicine will be provided free of charge. Travel expenses may also be reimbursed.

Was passiert, wenn ich meine Meinung über die Teilnahme ändere?

You have the right to leave the study at any time, for any reason, without having to explain why. Your decision will not affect your ongoing medical care.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.